🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honored to be recognized as a Highly Cited Researcher for 2024—special thanks to the impactful global collaboration on gastric cancer research! #HighlyCited2024 clarivate.com/highly-cited-r…

Educational session on #TargetedTherapies for #GICancers in @myesmo #ESMOAsia24 😊Lots ongoing 🧺Tumour agnostic approach? depending on the target 🤝Much to learn from each other 🤔Does your #MolecularTesting cover your needs? 🤩Kohei shitara Filippo Pietrantonio Dominik Paul Modest

Excellent table to show all the current data of CAR-T therapy in GI cancers. Note that median PFS is not more than 3 to 6 months . And most of the trials have very small number of pts. By Kohei shitara ASCO #GI25 LARVOL

LEAP15 for gastric cancer did not meet OS endpoint. Drop of chemo or dose of LEN/toxicities matter? Need learn from negative trial OncoAlert OncoDaily merck.com/news/merck-and…

Pleased to share P2 results of futibatinib for FGFR2-amplified gastric cancer: ORR 17.9%. Shows some activity but underscores need for better options. Eagerly awaiting P3 chemo + bemarituzumab data OncoAlert ESMO - Eur. Oncology OncoDaily ejcancer.com/article/S0959-…

DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! OncoAlert OncoDaily Daiichi Sankyo US AstraZeneca daiichisankyo.com/files/news/pre…

Mattehorn study showed EFS improvement and strong OS trend with FLOT+duravalumab. Great news to establish the global standard for fit patients with locally advanced gastric/GEJ cancer. Looking forward to the detail.OncoAlert OncoDaily astrazeneca.com/media-centre/p…

Excited to share biomarker analysis of CM649 Nature Medicine Yelena Y. Janjigian MD Nivo benefit was enriched in TMB-H> EBV and GS > CIN. Targeted tx is needed for CIN. Nivo+Ipi benefit was seen in Treg↑ (FOXP3+CCR8), supporting Treg or CCR8 targeting tx in GC. nature.com/articles/s4159…

Thrilled to share our latest Review on Gastric Cancer in the The Lancet covering the latest in the treatment and management of this illness Lizzy Smyth Kohei shitara Hanneke van Laarhoven Sheraz Markar Yelena Y. Janjigian MD & Izuma Nakayama. thelancet.com/journals/lance…

Presented at #ASCO25: In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial:

エンハーツが胃癌の標準治療をまた塗り替えました。NEJMへ同時掲載。 今回も、　Kohei shitara 先生が筆頭。同じ日本人として誇りに思います。 #ASCO25 nejm.org/doi/full/10.10…

A tribute to Dr. Agatsuma was a meaningful moment during my DESTINY-Gastric04 presentation at #ASCO25 with NEJM publication. I deeply respect him and the entire team behind the development of T-DXd. ASCO OncoAlert Daiichi Sankyo Daiichi Sankyo US AstraZeneca Oncology at AstraZeneca

🚨 Late-breaking from #ASCO25: Dr. Kohei Shitara (Kohei shitara) presents LBA4002 – DESTINY-Gastric04! T-DXd challenges RAM+PTX in 2L HER2+ metastatic #gastriccancer & GEJA 🔬 Will this redefine the standard of care?tinyurl.com/3zm6wkeb #HER2Positive #ASCO2025 #ASCO25

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers ESMO Open ESMO - Eur. Oncology. The results of bemarituzumab phase 3 studies are awaited.OncoAlert OncoDaily sciencedirect.com/science/articl…

CLDN18 Expression and Isoform Distribution mainly in GI cancers. Trend of reduced overall CLDN18 expression after chemo with decrease CLDN18.2/18.1 proportion. Need similar analysis of isoform switch after chemo+Zolbe OncoAlert onlinelibrary.wiley.com/doi/10.1111/ca…

Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma in ESMO Open. 30% prevalence of FGFR2b protein expression, 53.9% of them negative for currently actionable biomarkers. esmoopen.com/article/S2059-…

The OncoAlert VJ Oncology JOURNAL CLUB This week we have the pleasure to bring you our OncoAlert Colleague Kohei shitara 🇯🇵Discussing his paper: Trastuzumab Durextecan or Ramucirumab plus paclitaxel in gastric cancer out on NEJM nejm.org/doi/10.1056/NE… #OncoAlertAF

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….

A novel gut bacterium, Hominenteromicrobium mutabilis YB328, boosts anti‑PD‑1 by activating CD103⁺CD11b⁻ dendritic cells → tumor-targeting CD8⁺ T cells migrate into tumors. Gut microbes could be next-gen immunotherapy adjuvants?nature nature.com/articles/s4158…

It’s my great honor to write the editorial for the pivotal MATTERHORN study NEJM Yelena Y. Janjigian MD ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.OncoAlert OncoDaily nejm.org/doi/full/10.10…